Presentation by Todd Hobbs, Chief Medical Officer, Hepion Pharmaceuticals, USA

Advancement of rencofilstat in NASH phase 2 – evaluating both structural and functional data

Share this article:

Creating a Bundle to Support Rencofilstat Success

Multiple targets have been addressed for NASH therapy reflecting the complex pathophysiology of this disease. CureDiab has identified thioacrylamidederivatives (HK1,3,4) that mediate allosteric activation of peripheral GABA-A receptors, resulting in a prominent hepatoprotection and an anti-fibrotic response. Pre-clinical studies were conducted using hepatocytes under lipotoxic conditions, activated human stellate cells and a mouse model of fibrosis. The preventive effect of HK was demonstrated by reduced caspase 3/7 activity in HepG2 and primary human hepatocyte.